APA (7th ed.) Citation

F, G., Z, T., A, C., A, T., İ, A., F, L., . . . V, F. (2025). A real-world study assessing the efficacy and safety of switching from basal bolus insulin therapy to once daily iGlarLixi in people with type 2 diabetes mellitus: Soli de-escalation. Diabetes research and clinical practice, 229, 112945. https://doi.org/10.1016/j.diabres.2025.112945

Chicago Style (17th ed.) Citation

F, Giorgino, Taybani Z, Cheng A, Tebaibia A, Anaforoglu İ, Lauand F, Servera S, Li X, and Fonseca V. "A Real-world Study Assessing the Efficacy and Safety of Switching from Basal Bolus Insulin Therapy to Once Daily IGlarLixi in People with Type 2 Diabetes Mellitus: Soli De-escalation." Diabetes Research and Clinical Practice 229 (2025): 112945. https://doi.org/10.1016/j.diabres.2025.112945.

MLA (9th ed.) Citation

F, Giorgino, et al. "A Real-world Study Assessing the Efficacy and Safety of Switching from Basal Bolus Insulin Therapy to Once Daily IGlarLixi in People with Type 2 Diabetes Mellitus: Soli De-escalation." Diabetes Research and Clinical Practice, vol. 229, 2025, p. 112945, https://doi.org/10.1016/j.diabres.2025.112945.